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Objective. The chemokine receptor CXCR4 and its ligand CXCL12 have been suggested to play important roles in the initiation or
progression of cancers. The goal of the present study was to investigate alterations of CXCL12/CXCR4 in oral premalignant lesions
and oral squamous cell carcinoma (OSCC). Methods. In 13 normal oral epithelia, 24 dysplastic oral leukoplakia (OLK), and 40
OSCC specimens, expressions of CXCL12 and CXCR4 were evaluated by immunohistochemistry. Results. CXCR4 was expressed in
37.5%ofOLKand60%ofOSCC.CXCL12wasdetectedin50%ofOLKand62.5%ofOSCC.InOLK,CXCR4positiveratioshowed
no signiﬁcant diﬀerence from normal epithelia, but the CXCL12 positive ratio was signiﬁcantly higher. Signiﬁcant relationship
between CXCL12 and CXCR4 was found both in OLK and OSCC. Conclusion. Our results indicated that CXCL12/CXCR4 axis
may play roles from early steps of oral malignant transformation and contribute to the progress of oral carcinogenesis.
1.Introduction
Oral squamous cell carcinoma (OSCC) accounts for approx-
imately 90% of oral malignancies. Approximately 274,000
newcasesannuallyarediagnosedworldwidewithonlya50%
survival rate over 5 years despite improved methods of
diagnosis and therapy [1]. OSCC is of epithelial origin and
mostly experiences a premalignant stage. Prevention of this
malignancy requires a better understanding of its carcino-
genesis process [2, 3]. However, the underlying mechanism
still remains enigmatic.
Chemokines, a group of small (approximately 8–17kDa)
chemotactic cytokines that bind to speciﬁc G-protein-cou-
pled seven-span transmembrane receptors, are essential
mediators of leukocyte migration in the immune system.
Chemokinesareinvolvedincellularinteractionsandtropism
in situations frequently associated with inﬂammation. Che-
mokines and their receptors play important roles in inﬂam-
mation, infection, tissue injury, allergy, and cardiovascu-
lar diseases. Recently, the importance of chemokines and
chemokine receptors has been highlighted in the initiation
and progression of cancers [4, 5]. Among those chemokines
and their receptors, the stromal cell-derived factor-1 (also
CXCL12) and its CX chemokine receptor 4 (CXCR4), a
protein frequently overexpressed on the surface of human
tumor cells of epithelial origin, have received considerable
attention. To date, CXCR4 has been demonstrated to be
overexpressed in more than 23 human cancers, including
breast cancer, ovarian cancer, and oral cancer. Although
CXCR4 is expressed in a broad array of tissues, CXCR4
expression is low or absent in many normal tissues, such
as breast and ovary [6, 7]. Signiﬁcant correlation between
CXCR4 expression and lymph-node metastasis was found
in OSCC patients. Treatment with CXCL12 enhanced the
motility and invasiveness of OSCC cells expressing CXCR4
[8]. Although recently attentions have been paid to the
relationship between CXCR4 and oral cancer, until now, no
report focuses on the alterations of CXCL12/CXCR4 axis in
premalignant stage of oral cancer.
Oral leukoplakia (OLK) is the most common oral pre-
cancerous lesion. Leukoplakic oral epithelia provide a useful
model for exploring the molecular mechanisms of oral
carcinogenesis [3, 9]. In this study, we set out to evaluate the
protein expressions of CXCL12 and CXCR4 by immunohis-
tochemistryinsurgicallyresectednormaloralepithelia,OLK
specimens with epithelial dysplasia, and OSCC tissues. Then,2 Mediators of Inﬂammation
therelationshipofCXCL12andCXCR4inoralpremalignant
and malignant lesions was investigated.
2.MaterialsandMethods
2.1. Subjects and Samples. A total of 77 subjects, including
24 OLK patients, 40 OSCC patients, and 13 healthy persons,
were enrolled in the present study from Guanghua School
of Stomatology, Sun Yat-Sen University, China. The subjects
were aged between 24 and 78 years. No subjects had radio-
therapy, chemotherapy, or other interventional palliative or
therapeutic measures prior to sampling. All subjects partici-
patedin this study withwrittenconsents, andtheprojectwas
approved by the Institutional Review Board.
All the surgically resected specimens were formalin ﬁxed
and paraﬃn-embedded using conventional histopathologi-
cal techniques for both histopathological examination and
subsequent immunohistochemistry analysis. Histopatholog-
icalevaluationwasperformedaccordingtotheWHOcriteria
for histological typing of cancer and precancer of the oral
mucosa by the Department of Pathology, Guanghua School
of Stomatology.
2.2. Immunohistochemistry. The polyclonal primary rabbit
antibodies against CXCL12 (1:400, Abcam Inc., Cambridge,
MA, UK) and polyclonal primary goat antibodies against
CXCR4 were used (1:300, Abcam Inc., Cambridge, MA,
UK). Immunohistochemistry was performed using the
S u p e r P i c t u r e ,a3 r dG e nI H CD e t e c t i o nK i t( i n v i t r o g e n ,U S ) ,
and Polink-2 plus Polymer HRP Detection System For Goat
Primary Antibody (Golden Bridge International Inc., US)
according to the manufacturer’s recommendations.
4-µms e c t i o n so fp a r a ﬃn-embedded specimens were
deparaﬃnized in xylene (twice) and treated with a graded
series of alcohol (100%, 95%, and 80% ethanol/double-
distilled H2O2 (v/v)), and rehydrated in phosphate buﬀered
saline (PBS, pH 7.4). Antigen retrieval was performed by
incubatingtissuesectionsimmersedin0.01Msodiumcitrate
buﬀer(pH6.0)inamicrowaveoven.Endogenousperoxidase
was inactivated using 3% hydrogen peroxide for 10min.
After rinsing with PBS, normal goat serum for 10min was
applied to reduce nonspeciﬁc staining. The sections were
incubated with polyclonal primary antibodies at 37◦Cf o r
40min (CXCL12) or at 4◦C overnight (CXCR4). After wash-
ing with PBS for 5min, the sections were incubated for
10min with biotinylated secondary antibody, washed with
PBS, then incubated for 10min with the streptavidin-horse-
radish peroxidase (HRP) solution, which binds to the biotin-
labelled secondary antibody present to the tissue. After PBS
rinsing, staining of sections was performed by incubation for
5min with 3,3-diaminobenzidine tetrahydrochloride (DAB)
in H2O2. After washing with water, the sections were coun-
terstained with hematoxylin for 3min. Negative controls for
each biopsy were processed in the same manner, using PBS
instead of the primary antibody. Human spleen tissue and
hepatocarcinoma tissue were used as positive controls for
CXCR4 and CXCL12, respectively.
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Figure 1: Positive ratios of CXCR4 and CXCL12 in oral premalig-
nant lesions and oral cancers by immunohistochemistry analysis.
∗P<0.05, compared with normal epithelia.
2.3. Immunohistochemistry Analysis. Expressions of CXCR4
and CXCL12 were quantiﬁed using a visual grading system
based on the extent of staining (percentage of positive cells
graded on scale from 0 to 4: 0, <5%; 1, 5–25%; 2, 25–50%;
3, 50–75%; 4, >75%) and the intensity of staining (graded
on a scale of 0–3: 0, none; 1, weak staining; 2, moderate
staining;3,strongstaining).Fiverepresentativeﬁeldsat ×400
magniﬁcation were evaluated. A weighted score was assigned
to each case by multiplying the score for the percentage
of positive cells by the staining intensity score. Cases with
a weighted score of less than 1 were considered negative;
otherwise they were considered positive [10].
2.4. Statistical Analysis. Chi-square analysis was used to esti-
mate statistical diﬀerence of positive ratios among diﬀerent
groups during oral carcinogenesis. Probability value of P<
0.05 (two-sided) was accepted as statistically signiﬁcant for
all statistical tests carried out using SPSS version 13.0 soft-
ware (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Expressions of CXCR4 and CXCL12 Proteins in OLK
and OSCC Tissues. CXCR4 was expressed in 9 out of 24
OLK cases (37.5%; Figure 1). Of the 40 OSCC cases, 24
(60%) had uniformly detectable CXCR4 immunostaining.
However, the positive ratio of CXCR4 was only 15.4%
(2 of 13 cases with weak staining) in normal tissue. No
signiﬁcant diﬀerence of CXCR4 positive ratio was found
between normal tissue and OLK, but in OSCC the positive
ratio increased and was signiﬁcantly higher than that in
normalepithelia(P = 0.005 < 0.05),withoutdiﬀerencefrom
OLK tissues (P = 0.081 > 0.05). CXCR4 staining showed a
predominantly cytoplasmic distribution and some was also
detected in the cellular nucleus (Figure 2). Most normal
tissues displayed little or undetectable CXCR4 expression.
In both dysplastic and cancerous oral epithelia, the CXCR4
staining was distinct and spread in all the cell layers. Fur-
thermore, mild-moderate staining could also been observed
in some vascular endothelial cells within lamina propria
and submucosa of dysplastic and cancerous oral epithelia.Mediators of Inﬂammation 3
Table 1: Association of CXCL12 and CXCR4 expressions in OLK and OSCC tissues.
Histopathology Total cases (%) CXCL12-positive cases (%) CXCL12-negative cases (%) P∗
OLK 24 12 (50%) 12 (50%)
0.003 CXCR4-positive cases (%) 9 (37.5%) 8 (33.3%) 1 (4.2%)
CXCR4-negative cases (%) 15 (62.5%) 4 (16.7%) 11 (45.8%)
OSCC 40 25 (62.5%) 15 (37.5%)
0.001 CXCR4-positive cases (%) 24 (60.0%) 20 (50.0%) 4 (10.0%)
CXCR4-negative cases (%) 16 (40.0%) 5 (12.5%) 11 (27.5%)
∗Chi-square test, relationship between CXCL12 and CXCR4 expressions.
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Figure 2: CXCR4 expression in human normal epithelia (a), OLK with dysplasia (b), and OSCC epithelia (c) by method of immunohisto-
chemistry. Original magniﬁcations, ×200.
Figure 2 displayed representative CXCR4 immunostaining
with diﬀerent histopathological grading.
CXCL12 staining mainly distributed in the cytoplasm
and intercellular substances. Expression of CXCL12 was ob-
served in 12 of 24 OLK (50%; P = 0.01 < 0.05) cases and 25
of40OSCCcases(62.5%, P = 0.001 < 0.05),withsigniﬁcant
diﬀerence from that in normal epithelia (1 of 13 cases,
7.7%; Figure 1), respectively. No signiﬁcant diﬀerence was
indicated between OLK and OSCC tissues (P = 0.51 > 0.05).
Figure 3 displayed representative CXCL12 immunostaining
in patients’ samples.
3.2. Correlation of CXCL12 and CXCR4 Expression in OLK
and OSCC Tissues. Data analysis found that in 8 OLK and
20 OSCC specimens, which displayed positive staining of
CXCR4, expression of CXCL12 could also been detected
(Table 1). Signiﬁcant relationship between CXCL12 expres-
sion and CXCR4 expression was found both in OLK (P =
0.003 < 0.0 5 )a n dO S C Cs p e c i m e n s( P = 0.001 < 0.05).
4. Discussion
Oralcarcinogenesis is a multistep processand theunderlying
mechanism is still unclear. Recently, studies revealed that
cancer epithelial cells were producing higher levels of a num-
berofchemokinescomparedwithnormalepithelialcellsand
were also expressing high levels of a series of chemokine re-
ceptors, to establish a tumor-promoting microenvironment,
facilitating tumor-associated angiogenesis and metastasis
[11]. Our previous study indicated that CXCR7 expression
might be involved in oral carcinogenesis [3].In this study, we
demonstrated for the ﬁrst time changes of CXCL12/CXCR44 Mediators of Inﬂammation
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Figure 3: CXCL12 immunostaining in human normal epithelia (a), OLK with dysplasia (b), and OSCC epithelia (c). Original magniﬁca-
tions, ×200.
chemokine axis in oral premalignant lesions and their poten-
tial roles in oral carcinogenesis.
CXCR4 was expressed in 60% of 40 OSCC cases in our
study. Our data were similar to that of two previous reports,
which showed that the positive staining ratios were 62.6%
and 57.3% in OSCC patients, respectively [12, 13]. All these
suggested the tight relationship between CXCR4 and OSCC.
CXCR4 expression is upregulated in malignant cells via
several mechanisms. Ishikawa et al. [14] found a signiﬁcant
correlation between the expression of CXCR4 and HIF-1
alpha in OSCC tissues. HIF-1 is a heterodimeric transcrip-
tion factor responsive to oxygen concentrations in tissues
and has been shown to upregulate CXCR4 expression. Our
results also showed that expression of its ligand CXCL12 was
observed in 62.5% of 40 OSCC cases. In 24 CXCR4-positive
cases of OSCC, CXCL12, and CXCR4 were coexpressed in 20
cases. When compared with normal tissue, both CXCR4 and
CXCL12 positive ratios in OSCC were signiﬁcantly higher
and a signiﬁcant correlation was found between them. All
those indicated the roles of CXCL12/CXCR4 axis in OSCC.
Furthermore, of the 24 oral premalignant lesions (OLK
cases), data analysis found that 37.5% displayed CXCR4
positive staining and 50% displayed CXCL12 positive stain-
ing. Although CXCR4 positive ratio showed no signiﬁcant
diﬀerence between OLK and normal epithelia, the posi-
tive ratio of CXCL12 increased signiﬁcantly from normal
epithelia. In 9 CXCR4 positive cases of OLK, 8 cases dis-
played CXCL12 positive staining. Further data analysis still
found a signiﬁcant relationship between CXCL12 expression
and CXCR4 expression in OLK, just similar to that in
OSCC tissues. All those demonstrated that CXCL12/CXCR4
axis might begin playing roles from early steps of oral
malignant transformation and contribute to the progress of
oral carcinogenesis. Binding of CXCL12 to CXCR4 could
trigger activation of many downstream targets, including
ERK1/2, MAPK, JNK, and AKT eﬀectors. CXCL12/CXCR4
axis activated extracellular signal-regulated kinase (ERK)1/2
andAkt/proteinkinaseB(PKB)inOSCCcells,andtheirsyn-
thetic inhibitors attenuated the chemotaxis by SDF-1. SDF-1
alsoactivatedSrcfamilykinases(SFKs),anditsinhibitorPP1
diminished the SDF-1-induced chemotaxis and activation
of both ERK1/2 and Akt/PKB [15]. Ligand-stimulated
chemotaxis is accompanied by cytoskeletal rearrangements,
actin polymerization, polarization, pseudopodia formation,
and integrin-dependent adhesion to endothelial cells and
otherbiologicsubstrates[16–18].Untilnow,veryfewreports
concerned the biological functions and related signaling
pathways of CXCL12/CXCR4 axis in the progression of
OSCC. CXCR4-knockdown OSCC cells showed reduced
invasiveness and grew signiﬁcantly slower than the vector-
infected control cells [19]. CXCR4 promoted OSCC migra-
tion and invasion through inducing expression of MMP-9,
13 via the ERK signaling pathway [20, 21]. All these suggest
that the downregulation of CXCR-4 induces antiproliferative
and antiinvasive eﬀects in OSCC and that CXCR-4 might
be a useful target molecule for the treatment of OSCC.
Uchida et al. [22] showed that subcutaneous administra-
tion of AMD3100 (CXCR4 inhibitor) signiﬁcantly inhibitedMediators of Inﬂammation 5
the lymph node metastases of OSCC cells when they were
inoculated into the masseter muscle of nude mice.
Taken together, these ﬁndings support the hypothesis
that CXCL12/CXCR4 may play important roles in oral
premalignant stages, contributing to the progress of oral
carcinogenesis. However, much about the mechanisms of
CXCL12/CXCR4 axis in oral carcinogenesis still let to be
known. Notably, blockage of CXCR4 as well as its ligands
CXCL12 during oral cancer promotion could be employed
as a new therapeutic strategy in future.
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